Immunohistochemical expression of heparin-binding protein 17/fibroblast growth factor-binding protein-1 (HBp17/FGFBP-1) as an angiogenic factor in head and neck tumorigenesis.

Immunohistochemical expression of heparin-binding protein 17/fibroblast growth factor-binding protein-1 (HBp17/FGFBP-1) as an angiogenic factor in head and neck tumorigenesis.
复制标题

DOI:
10.3892/or.17.3.591
复制
发表时间:
2007-03
期刊:
影响因子:
4.2
通讯作者:
Shahanaz Begum;Yan Zhang;T. Shintani;S. Toratani;J. Sato;T. Okamoto
Shahanaz Begum;Yan Zhang;T. Shintani;S. Toratani;J. Sato;T. Okamoto
中科院分区:
医学3区
文献类型:
--
作者:
Shahanaz Begum;Yan Zhang;T. Shintani;S. Toratani;J. Sato;T. Okamoto

文献摘要

被引文献

相似文献

肝素结合蛋白17/成纤维细胞生长因子结合蛋白-1(HBp 17/FGFBP-1)是一种分泌性蛋白,其从细胞外基质释放固定的成纤维细胞生长因子-2(FGF-2),并且在FGF生物活化中起关键作用。在本研究中,FGF-2和HBp 17/FGFBP-1共定位在口腔组织,包括正常粘膜,增生,不同程度的不典型增生和口腔鳞状细胞癌(OSCC)。HBp 17/FGFBP-1、FGF-2和血管内皮生长因子A(VEGF-A)的表达评分随着上皮异型增生的严重程度而升高,在重度异型增生中最高。HBp 17/FGFBP-1、FGF-2和VEGF-A的表达与微血管密度(MVD)显著相关,而与TNM分期和复发时间无关。我们的研究结果表明,HBp 17/FGFBP-1,像VEGF-A和FGF-2,也可能促进肿瘤血管生成的诱导。血管生成因子在严重发育不良中的最强表达提示了针对新型抗血管生成治疗策略的潜在点。
Heparin-binding protein 17/fibroblast growth factor-binding protein-1 (HBp17/FGFBP-1) is a secreted protein that releases immobilized fibroblast growth factor-2 (FGF-2) from the extracellular matrix and plays a critical role in FGF bioactivation. In the present study co-localization of FGF-2 and HBp17/FGFBP-1 was observed in oral tissues including normal mucosa, hyperplasia, dysplasia of different degrees and oral squamous cell carcinoma (OSCC). The expression score for HBp17/FGFBP-1, FGF-2 as well as vascular endothelial growth factor A (VEGF-A) became higher with the severity of epithelial dysplasia and was highest in severe dysplasia. The expression of HBp17/FGFBP-1, FGF-2 and VEGF-A showed significant association with microvessel density, but no correlation with TNM stages or OSCC recurrence interval. Our results demonstrated that HBp17/FGFBP-1, like VEGF-A and FGF-2, might also promote the induction of tumor angiogenesis. The strongest expression of angiogenic factors in severe dysplasia suggests a potential point for targeting novel anti-angiogenic therapeutic strategies.